The specter of generic rivalry has long loomed above copyright’s iconic drug, Sildenafil, raising questions about the future of connected drug portfolios. While early years saw substantial returns, the exclusivity lapse has created the door for cheaper alternatives, potentially diminishing revenue and creating a significant hazard for stakeholder